Clinical Trials Logo

Refractory Glioblastoma clinical trials

View clinical trials related to Refractory Glioblastoma.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06404034 Available - Glioblastoma Clinical Trials

Expanded Access to Gallium Maltolate (GaM)

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments. The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria. Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes